Assessment of the phenotype of the type 2 diabetic responders to the first insulinisation using Lantus (insulin glargine) plus glucophage (metformin) combination after failure in OADs [oral antidiabetics] treatment

Trial Profile

Assessment of the phenotype of the type 2 diabetic responders to the first insulinisation using Lantus (insulin glargine) plus glucophage (metformin) combination after failure in OADs [oral antidiabetics] treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Apr 2008

At a glance

  • Drugs Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GALATEE
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top